Results 71 to 80 of about 2,912 (167)

Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials

open access: yesNeurotherapeutics
Leukodystrophies are progressive single gene disorders affecting the white matter of the brain. Several gene therapy trials are in progress to address the urgent unmet need for this patient population.
Jasna Metovic   +3 more
doaj   +1 more source

ePosters Virtual

open access: yes
European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

GM2 activator protein deficiency, mimic of Tay-Sachs disease

open access: yes, 2017
GM2 Gangliosidoses are a group of autosomal recessive genetic disorders caused by intra-lysosomal deposition of ganglioside GM2 mainly in the neuronal cells.
Sheela Nampoothiri   +5 more
core   +1 more source

Long Term Correction of GM2 Gangliosidoses in Sandhoff Mice Through Intravenous Neonatal Gene Therapy, Using a Recombinant Adeno-Associated Viral Vector Expressing a New Hexosaminidase Variant

open access: yes, 2015
Thesis (Master, Neuroscience Studies) -- Queen's University, 2015-12-11 17:45:21.072GM2 gangliosidoses are a group of neurodegenerative disorders, characterized by the malfunctioning β-Hexosaminidase A (HexA) enzyme, for which there is no current ...
Osmon, Karalaina
core  

Similarities and differences in the late-onset GM2 gangliosidoses: Tay-Sachs and Sandhoff diseases. [PDF]

open access: yesJ Neurol
Lewis CJ   +16 more
europepmc   +1 more source

Symptomatic Benefit of Acetyl-DL-Leucine for Cerebellar Ataxia in Juvenile Tay-Sachs Disease: A Pediatric Case and Literature Review. [PDF]

open access: yesMol Syndromol
Calisgan K   +7 more
europepmc   +1 more source

GM2 Gangliosidosis AB Variant: A Hidden Truth. [PDF]

open access: yesCureus
Noites I   +9 more
europepmc   +1 more source

Metabolomic Insights into Lysosomal Storage Diseases: An Untargeted View. [PDF]

open access: yesMetabolites
Di Carlo G   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy